Imagion Biosystems Limited
IBXXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | 0.03 | 0.05 |
| FCF Yield | -73.04% | -34.40% | -1.25% | -5.36% |
| EV / EBITDA | -4.23 | -21.10 | -28.51 | -7.41 |
| Quality | ||||
| ROIC | 311.24% | 20.31% | 41.81% | -205.64% |
| Gross Margin | -2,276.60% | 93.38% | 79.64% | 165.87% |
| Cash Conversion Ratio | 1.07 | 2.06 | 0.10 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.67% | 9.44% | 5.62% | 35.63% |
| Free Cash Flow Growth | -59.59% | -609.62% | 93.63% | 59.24% |
| Safety | ||||
| Net Debt / EBITDA | -2.11 | -1.09 | -5.22 | -0.83 |
| Interest Coverage | -2.59 | -1.72 | -0.72 | -11.03 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -217.28 | -2,737.88 | -700.34 | -38.16 |